Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 18/20 | 1.00 |
| ▸ | HTR2C | P28335 | 18/20 | 1.00 |
| ▸ | HTR2B | P41595 | 9/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | HTR1D | P28221 | 1/20 | 1.00 |
| ▸ | HTR7 | P34969 | 1/20 | 1.00 |
| ▸ | HTR4 | Q13639 | 1/20 | 1.00 |
| ▸ | KMO | O15229 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL475894 | 1.00 | HTR2A (1.00) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL31079586 | 1.00 | HTR2A (1.00) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL6088764 | 1.00 | HTR2A (1.00) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL27561126 | 0.89 | HTR2A (0.80) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL27645810 | 0.88 | HTR2A (0.78) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL5843607 | 0.86 | HTR2A (0.76) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL4950686 | 0.86 | HTR2A (0.76) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL10252671 | 0.83 | HTR2A (0.71) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL28069280 | 0.83 | HTR2A (0.71) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL28069278 | 0.83 | HTR2A (0.71) | HTR2AHTR2CHTR2BHTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360150-A1 | METHODS OF USING NEUROPLASTIC AGENTS AND TERRAFORMING MARS | BRANNOCK METCALF MOLLY CAROLINE (US) | 2025-11-27 | — | — | US | claimed |
| US-20220146492-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2022-05-12 | — | — | US | claimed |
| EP-3953000-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | Shine, Ian Basil (US) | 2022-02-16 | — | — | EP | claimed |
| US-20060073172-A1 | Stabilized ophthalmic solution for the treatment of glaucoma and lowering intraocular pressure | SCHNEIDER L W | 2006-04-06 | — | — | US | claimed |
| US-6927233-B1 | 5ht2 agonists for controlling IOP and treating glaucoma | ALCON, INC. (CH) | 2005-08-09 | — | — | US | claimed |
| EP-1267847-B1 | 5HT 2 AGONISTS FOR CONTROLLING IOP AND TREATING GLAUCOMA | ALCON INC (CH) | 2004-02-04 | — | — | EP | claimed |
| EP-1267847-A2 | 5HT 2 AGONISTS FOR CONTROLLING IOP AND TREATING GLAUCOMA | Alcon Inc. (CH) | 2003-01-02 | — | — | EP | claimed |
| WO-2002098861-A1 | METHODS OF MAKING 1-(2-AMINOPROPYL)-6-HYDROXYINDAZOLE | ALCON, INC. (CH) | 2002-12-12 | — | — | WO | claimed |
| WO-2001070207-A2 | 5HT2 AGONISTS FOR CONTROLLING IOP AND TREATING GLAUCOMA | ALCON, INC. (CH) | 2001-09-27 | — | — | WO | claimed |
| US-20250360150-A1 | METHODS OF USING NEUROPLASTIC AGENTS AND TERRAFORMING MARS | BRANNOCK METCALF MOLLY CAROLINE (US) | 2025-11-27 | — | — | US | disclosed |
| US-20220146492-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2022-05-12 | — | — | US | disclosed |
| US-11278549-B2 | Method of treating obesity | MCMASTER UNIVERSITY (CA) | 2022-03-22 | — | — | US | disclosed |
| EP-3953000-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | Shine, Ian Basil (US) | 2022-02-16 | — | — | EP | disclosed |
| US-20140350064-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC | 2014-11-27 | — | — | US | disclosed |
| WO-2002098861-A1 | METHODS OF MAKING 1-(2-AMINOPROPYL)-6-HYDROXYINDAZOLE | ALCON, INC. (CH) | 2002-12-12 | — | — | WO | disclosed |
| WO-2001070207-A3 | 5HT2 AGONISTS FOR CONTROLLING IOP AND TREATING GLAUCOMA | ALCON UNIVERSAL LTD (CH) | 2002-05-10 | — | — | WO | disclosed |
| WO-2001070701-A1 | 5-HYDROXY INDAZOLE DERIVATIVES FOR TREATING GLAUCOMA | ALCON, INC. (CH) | 2001-09-27 | — | — | WO | disclosed |
| WO-2001070207-A2 | 5HT2 AGONISTS FOR CONTROLLING IOP AND TREATING GLAUCOMA | ALCON, INC. (CH) | 2001-09-27 | — | — | WO | disclosed |
| WO-2001070207-A2 | 5HT2 AGONISTS FOR CONTROLLING IOP AND TREATING GLAUCOMA | ALCON, INC. (CH) | 2001-09-27 | — | — | WO | disclosed |
| WO-2001070702-A1 | 6-HYDROXY-INDAZOLE DERIVATIVES FOR TREATING GLAUCOMA | ALCON, INC. (CH) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11278549-B2 | Method of treating obesity | GPR119, HTR2A, GIPR | HTR2A 2/4885HTR2C 20/4885HTR2B 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.